Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

The SOLO2/ENGOT-Ov21 Investigators

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)535-536
Number of pages2
JournalObstetrical and Gynecological Survey
Volume76
Issue number9
DOIs
StatePublished - 1 Sep 2021

Cite this